GENE ONLINE|News &
New Test Detects Biomarkers for Frontotemporal Lobar Degeneration, a Rare Dementia Affecting Over 57 Million Globally
A new ultrasensitive test can detect biomarkers for frontotemporal lobar degeneration (FTLD), a rare form of dementia. Currently, biomarkers exist for diagnosing Alzheimer’s disease (AD), but not for FTLD or its subtypes. Dementia affects over 57 million people globally, and experts project this number to double in the next two decades.
The permanent loss of cognitive abilities associated with dementia impacts daily function and can stem from various brain pathologies. While Alzheimer’s disease is a well-known cause, other conditions like frontotemporal lobar degeneration can also lead to dementia. The new test offers a way to identify this rarer pathology through specific biomarkers, which was previously unavailable.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: May 10, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Hilton Partners With Big Brothers Big Sisters to Provide Hospitality Career Training for Youth
2026-06-18
Pacific Life Launches Income Horizon Collective Investment Trust Series for Retirement Plans
2026-06-18
Synovis Micro Companies Alliance to Distribute MediThinQ SHIYA 3D Visualization Platform Globally
2026-06-18
Diamond Estates Wines & Spirits Inc. Renews Investor Relations Agreement with Atrium Research
2026-06-18
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
